

# BMI CHART

Hiranandani Fortis Hospital

Sector 10 - A, Vashi, Navi Mumbai - 400 703.

Tal.: +91-22-3919 9222 Fax: +91-22-3919 9220/21 Email: vashi@vashihospital.com

Date: 13 101124

Sex: M/F

*			983							Cauchel		185	8770	175	160	185	190	195	200	205	210	215
WEIGHT lbs	100 165	1,00	115	120 3	(28) I	30 1	95. 44 2 4 44	8 14A 8 88.9	68.2	70.5	12.7	78.0	77.3	79.5	84.8	64.4	86.4	88.6	90.9	93.2	95,5	
kgs	45.5 47.7		52.5	54.6				9 900	W-1-1	lä	rwiig	EL.		EVE	Obst	ă		8	Extr	_		- CONTROL
HEIGHT In/cm	Und	erweig	62 2 86.	1	1	tealth.	y management		No.	3	134	32	33	34	35	35	37	38	39	40		42
5'0" - 152.4	19 20	21	22	23	24 M	25 1 2	16 127	11.28	1	26	158	31	32	33	34	35	36	36	37	38	39	40
A COLUMN TO THE REAL PROPERTY OF THE PARTY O	18 19	26 8	21	22 🟭	23 📳	24 11 2	# #	11 27	emi	28	28	30	31	32	33	33	34	35	36	37	38	39
5'1" - 154.9	18 19	20	21	22	22	23 2	24 25	26		27	38	129	30	131	32	12	33	34-	35	36	37	38
5'2" - 157.4	17 18	19	20	21	22	23	24 24	25	2.6	1 47 1 ====		178	1/29	35	131	135	32	33	34	35	36	37
5'3" - 160.0 ·	17 18	15	19	20 ]	21 1	27	28 1 2	6 MM 24	4.00 100 100 100 100 100 100 100 100 100	1		107	122	127	30	10	34	32	33	34	35	35
5'4" - 162.5	16 117	1513	1927	20 [	20	23 [	20 2	9 (4) 34	94 50	100	40.0	26	-	-	29	175	30	21	32	33	34	34
5'5" - 165.1	16 17	17	18	19	20	25	25 3	2 2	49		100	100				1500	1179	30	31	32	33	33
5'6" - 167.6	115 118	147	4.5	149	150 E	70	94 9	20 10 25			Fig. 11	Top.	15.		127	Ton	28	1 29	30	31	32	32
5'7" - 170.1	15 16	16	49	4.0	19 ]	10	201	14		H			All the law	-0.5	100	15.	28	28	29	30	31	31
5'8" - 172.7	15 16	16	17	47	48	19 18	20	2	100	100		5 00	9	T for	95		107	100	28	29	30	30
5'9" - 176.2	14 15	4-1	16	17	18	48 1/1	19H	20 1 2		20		7	1	The second	0.2	11-	1126	27	2.8	28	29	
5'10" - 177.8	14 1	THE R. P. LEW.	198	16	4.7	45	1315	10.8	2	1			Ŧ-	-	11 2	7	55	1/20	27	27	28	
5'11" - 180.3	62 4		003	11	1	47	11	15 18						ā.	9.	V.	11 20	7.	20	2	7 27	28
6'0" - 182.8	42 1		13	15	16	127	17	18.85	1914	214	11		T v	Ă.		1	2		2	5 2	6 27	27
6'1" - 185.4	40 0	9 12	14	15	45	15	17	12	1881 1	230	·	700	-			18.5	61 -	1	2	5 2	5 26	26
6'2" - 187.9	12	v 42	44	88	- 6	10	417	17	10 1	100	1		Value of	100	1	- 10 >	8.0	2 2	2 2	4 2	5 2	5 26
6'3" - 190.5	20		200 E	11	-	45		0	17			, i		A lower of					-			
6'4" - 193.0		(e)	ALPRON TO THE			. >													3			

Doctors Notes:			
DOCIOIS 110 SEE			
s *	The second secon	THE PARTY OF THE P	
			3
	E		
	2 22	and the same of th	
*			
		e	
	The second secon	4 5 7	
	10-4 - 17-3	₹	1960
A THE RESERVE OF THE PARTY OF T			- F
		, the	
	4 W/A Sa - Benza	The second second	
	and the same of th		
The state of the s			
	*		
			*
	A CONTRACTOR OF THE CONTRACTOR		625
			· · · · · · · · · · · · · · · · · · ·
			*
,			







CODE/NAME & ADDRESS : C( 00045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO : 0022XA002426

: FH.12921812 PATIENT ID CLIENT PATIENT ID: UID:12921812

ABHA NO

Female AGE/SEX :41 Years

:13/01/2024 12:49:00 DRAWN RECEIVED: 13/01/2024 12:49:24

REPORTED :13/01/2024 14:28:14

CLINICAL INFORMATION:

UID:12921812 REQNO-1650220 CORP-OPD BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

**Test Report Status** 

**Final** 

Biological Reference Interval Units

**BIOCHEMISTRY** 

Results

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

75

70 - 140

mg/dL

METHOD : HEXOKINASE

Comments

NOTE: - POST PRANDIAL PLASMA GLUCOSE VALUES, TO BE CORRELATE WITH CLINICAL, DIETETIC AND THERAPEUTIC HISTORY.

Interpretation(s)
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c

\*\*End Of Report\*\* Please visit www.agilusdiagnostics.com for related Test Information for this accession



Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist



Page 1 Of 1



Navi Mumbai, 400703

Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956









REF. DOCTOR: PATIENT NAME: MRS.RANU PATEL

CODE/NAME & ADDRESS: C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

ACCESSION NO: 0022XA002363

PATIENT ID : FH.12921812 CLIENT PATIENT ID: UID:12921812

ABHA NO

:41 Years Female AGE/SEX

:13/01/2024 10:28:00 DRAWN RECEIVED: 13/01/2024 10:28:35

REPORTED :13/01/2024 16:10:07

#### CLINICAL INFORMATION:

UID:12921812 REQNO-1650220 CORP-OPD BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

**Test Report Status** 

**Final** 

Results

Biological Reference Interval Units

ŀ	IAEMATOLOGY - CBC		
CBC-5, EDTA WHOLE BLOOD			9
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	12.1	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: HYDRODYNAMIC FOCUSING	4.34	3.8 - 4.8	mil/μL
WHITE BLOOD CELL (WBC) COUNT METHOD : FLUORESCENCE FLOW CYTOMETRY	5.40	4.0 - 10.0	thou/µL
PLATELET COUNT  METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION	175	150 - 410	thou/μL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD	35.6 Low	36.0 - 46.0	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	82.0 Low	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	27.9	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC) METHOD: CALCULATED PARAMETER	34.0	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	13.1	11.6 - 14.0	%
MENTZER INDEX METHOD: CALCULATED PARAMETER	18.9		
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	11.7 High	6.8 - 10.9	fL

### WBC DIFFERENTIAL COUNT



Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 



Page 1 Of 16



Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -









CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO: 0022XA002363

: FH.12921812 CLIENT PATIENT ID: UID:12921812

ABHA NO

PATIENT ID

AGE/SEX :41 Years Female DRAWN

:13/01/2024 10:28:00 RECEIVED: 13/01/2024 10:28:35

REPORTED :13/01/2024 16:10:07

#### CLINICAL INFORMATION:

UID:12921812 REQNO-1650220

CORP-OPD

BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units				
NEUTROPHILS	66	40.0 - 80.0	%			
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	00	40.0 - 80.0	370			
LYMPHOCYTES	24	20.0 - 40.0	%			
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			92707			
MONOCYTES	8	2.0 - 10.0	%			
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING		198	and the second s			
EOSINOPHILS	2	1 - 6	%			
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING			84			
BASOPHILS	0	0 - 2	%			
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT	2.56	2.0 - 7.0	thou/µL			
METHOD : CALCULATED PARAMETER	3.56	2.0 - 7.0	thou/pc			
ABSOLUTE LYMPHOCYTE COUNT	1.30	1.0 - 3.0	thou/µL			
METHOD : CALCULATED PARAMETER	1.50	1.0 5.0	thou, p.c.			
ABSOLUTE MONOCYTE COUNT	0.43	0.2 - 1.0	thou/µL			
METHOD : CALCULATED PARAMETER		.5.12	estations (Orange)			
ABSOLUTE EOSINOPHIL COUNT	0.11	0.02 - 0.50	thou/µL			
METHOD: CALCULATED PARAMETER						
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL			
METHOD: CALCULATED PARAMETER						
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	2.7					
METHOD: CALCULATED						

### MORPHOLOGY

**RBC** 

METHOD: MICROSCOPIC EXAMINATION

**WBC** 

METHOD: MICROSCOPIC EXAMINATION

**PLATELETS** 

METHOD: MICROSCOPIC EXAMINATION

PREDOMINANTLY NORMOCYTIC NORMOCHROMIC

NORMAL MORPHOLOGY

**ADEQUATE** 

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist





Page 2 Of 16



Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956









CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001

REF. DOCTOR: ACCESSION NO: 0022XA002363

PATIENT ID : FH.12921812

CLIENT PATIENT ID: UID:12921812 ABHA NO

AGE/SEX :41 Years Female DRAWN

RECEIVED: 13/01/2024 10:28:35 REPORTED :13/01/2024 16:10:07

:13/01/2024 10:28:00

CLINICAL INFORMATION:

UID:12921812 REQNO-1650220

CORP-OPD

BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

**Test Report Status** 

**Final** 

Results

Biological Reference Interval Units

Interpretation(s)
RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait
(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 





Page 3 Of 16



PERFORMED AT :

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO: 0022XA002363

: FH.12921812 CLIENT PATIENT ID: UID:12921812

ABHA NO

PATIENT ID

AGE/SEX :41 Years Female

DRAWN :13/01/2024 10:28:00 RECEIVED: 13/01/2024 10:28:35

REPORTED :13/01/2024 16:10:07

#### CLINICAL INFORMATION:

UID:12921812 REQNO-1650220

CORP-OPD

BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

**Test Report Status** 

**Final** 

Results

Biological Reference Interval

Units

#### HAEMATOLOGY

#### ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

E.S.R

METHOD: WESTERGREN METHOD

11

0 - 20

mm at 1 hr

### GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C

4.8

Non-diabetic: < 5.7

Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0

(ADA Guideline 2021)

METHOD: HB VARIANT (HPLC)

METHOD: CALCULATED PARAMETER

ESTIMATED AVERAGE GLUCOSE(EAG)

91.1

< 116.0

mg/dL

%

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm/hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Destran etc), Hypercholesterolemia
False Decreased: Polkilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

Dr. Akshay Dhotre, MD (Reg, no. MMC 2019/09/6377) Consultant Pathologist



Page 4 Of 16



Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956









Female

PATIENT NAME: MRS.RANU PATEL

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO: 0022XA002363

CLIENT PATIENT ID: UID:12921812

: FH.12921812

ABHA NO

PATIENT ID

AGE/SEX :41 Years DRAWN :13/01/2024 10:28:00

RECEIVED: 13/01/2024 10:28:35

REPORTED :13/01/2024 16:10:07

#### CLINICAL INFORMATION:

UID:12921812 REQNO-1650220

CORP-OPD

BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

**Test Report Status** 

**Final** 

Results

**Biological Reference Interval** 

Units

- 1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis; 10th edition.

  GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:
- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, to determine whether a patients metabolic control has remained continuously within the target range.

eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

HbA1c Estimation can get affected due to:

- HBA16 Estimation can get affected due to:

  1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HBA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

  2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

  3. Tron deficiency amenia is reported to increase test results. Hypertriglyceridemia uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

  4. Interference of hemoglobinopathies in HBA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist





Page 5 Of 16



Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

**REF. DOCTOR:** 

ACCESSION NO: 0022XA002363

CLIENT PATIENT ID: UID:12921812

: FH.12921812

ABHA NO

PATIENT ID

AGE/SEX DRAWN

:41 Years Female

:13/01/2024 10:28:00 RECEIVED: 13/01/2024 10:28:35

REPORTED :13/01/2024 16:10:07

CLINICAL INFORMATION:

UID:12921812 REQNO-1650220

CORP-OPD

BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

**Test Report Status** 

Results

**Biological Reference Interval** 

Units

#### **IMMUNOHAEMATOLOGY**

#### ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

TYPE B

RH TYPE

METHOD: TUBE AGGLUTINATION

**POSITIVE** 

METHOD: TUBE AGGLUTINATION

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist

Page 6 Of 16







Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322,

CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR :

ACCESSION NO: **0022XA002363**PATIENT ID : FH.12921812

CLIENT PATIENT ID: UID:12921812

ABHA NO

AGE/SEX :41 Years Female DRAWN :13/01/2024 10:28:00

RECEIVED : 13/01/2024 10:28:35 REPORTED :13/01/2024 16:10:07

#### CLINICAL INFORMATION:

UID:12921812 REQNO-1650220

CORP-OPD

BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

Test	Report	Status
------	--------	--------

<u>Final</u>

Results

Biological Reference Interval

Units

	BIOCHEMISTRY		
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL	0.57	0.2 - 1.0	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, DIRECT	0.19	0.0 - 0.2	mg/dL
METHOD : JENDRASSIK AND GROFF	0.38	0.1 - 1.0	mg/dL
BILIRUBIN, INDIRECT  METHOD: CALCULATED PARAMETER	0.30	0.1 - 1.0	mg/ac
TOTAL PROTEIN	7.5	6.4 - 8.2	g/dL
METHOD : BIURET	,	31, 31	
ALBUMIN	3.7	3.4 - 5.0	g/dL
METHOD : BCP DYE BINDING			
GLOBULIN	3.8	2.0 - 4.1	g/dL
METHOD: CALCULATED PARAMETER			ратто
ALBUMIN/GLOBULIN RATIO	1.0	1.0 - 2.1	RATIO
METHOD: CALCULATED PARAMETER ASPARTATE AMINOTRANSFERASE(AST/SGOT)	11 Low	15 - 37	U/L
METHOD: UV WITH PSP	11 1000	13 - 37	0/2
ALANINE AMINOTRANSFERASE (ALT/SGPT)	16	< 34.0	U/L
METHOD : UV WITH P5P			
ALKALINE PHOSPHATASE	68	30 - 120	U/L
METHOD : PNPP-ANP			6-24C)
GAMMA GLUTAMYL TRANSFERASE (GGT)	16	5 - 55	U/L
METHOD: GAMMA GLUTAMYLCARBOXY 4NITROANILIDE	400	01 024	1170
LACTATE DEHYDROGENASE	133	81 - 234	U/L
METHOD: LACTATE -PYRUVATE			
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR)	92	Normal : < 100	mg/dL
		Pre-diabetes: 100-125	
METHOD - HEVOLUTIAGE		Diabetes: >/=126	
METHOD : HEXOKINASE			

politica

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist



Page 7 Of 16







Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tel: 022-39199222,022-49723322,
CIN - U74899PB1995PLC045956
Email: -









REF. DOCTOR: PATIENT NAME: MRS.RANU PATEL

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

ACCESSION NO: 0022XA002363

PATIENT ID : FH.12921812 CLIENT PATIENT ID: UID:12921812

ABHA NO

AGE/SEX :41 Years

Female

:13/01/2024 10:28:00 DRAWN RECEIVED: 13/01/2024 10:28:35

REPORTED :13/01/2024 16:10:07

#### CLINICAL INFORMATION:

UID:12921812 REQNO-1650220 CORP-OPD BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

**Test Report Status** 

**Final** 

Results

Biological Reference Interval Units

#### **KIDNEY PANEL - 1**

### BLOOD UREA NITROGEN (BUN), SERUM

GLOMERULAR FILTRATION RATE (FEMALE)

BLOOD UREA NITROGEN METHOD : UREASE - UV

6

6 - 20

mg/dL

#### CREATININE EGFR- EPI

CREATININE

0.77

99.32

0.60 - 1.10

mg/dL

years

METHOD: ALKALINE PICRATE KINETIC JAFFES AGE

41

Refer Interpretation Below

mL/min/1.73m2

METHOD: CALCULATED PARAMETER

METHOD: CALCULATED PARAMETER

#### **BUN/CREAT RATIO**

BUN/CREAT RATIO

7.79

5.00 - 15.00

URIC ACID, SERUM

METHOD: URICASE UV

URIC ACID

3.9

7.5

2.6 - 6.0

mg/dL

TOTAL PROTEIN, SERUM

TOTAL PROTEIN METHOD : BIURET

6.4 - 8.2

g/dL

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist

Page 8 Of 16



Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -









CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO: 0022XA002363

PATIENT ID : FH.12921812

CLIENT PATIENT ID: UID:12921812

ABHA NO

AGE/SEX :41 Years Female

DRAWN :13/01/2024 10:28:00 RECEIVED: 13/01/2024 10:28:35

REPORTED :13/01/2024 16:10:07

### CLINICAL INFORMATION:

UID:12921812 REQNO-1650220 CORP-OPD BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

Test Report Status <u>Final</u>	D* I*-		
- Ina	Results	Biological Reference	e Interval Units
ALBUMIN, SERUM			
ALBUMIN METHOD: BCP DYE BINDING	3.7	3,4 - 5.0	g/dL
GLOBULIN			
GLOBULIN METHOD: CALCULATED PARAMETER	3.8	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM METHOD: ISE INDIRECT	140	136 - 145	mmol/L
POTASSIUM, SERUM METHOD: ISE INDIRECT	4.31	3.50 - 5.10	mmol/L
CHLORIDE, SERUM METHOD: ISE INDIRECT	105	98 - 107	mmol/L

#### Interpretation(s)

Interpretation(s)
LIVER FUNCTION PROFILE, SERUM-

ELIVER FUNCTION PROFILE, SERUMBilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when the same kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin attaches sugar molecules to bilirubin.



Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist



Page 9 Of 16

View Report



Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703

Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956









CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO: 0022XA002363

: FH.12921812 CLIENT PATIENT ID: UID:12921812

ABHA NO

PATTENT ID

AGE/SEX :41 Years Female :13/01/2024 10:28:00 DRAWN

RECEIVED: 13/01/2024 10:28:35

REPORTED :13/01/2024 16:10:07

#### CLINICAL INFORMATION:

UID:12921812 REQNO-1650220 CORP-OPD BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

Test Report Status

Results

Biological Reference Interval

Units

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strengous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GCT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum. GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Assessment of the control of the blood serum protein losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

urine.

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g. galactosemia), Drugs-insulin, ethanol, propramolol; suffonylurens, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure. Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE EGFR- EPI-- Kidney disease, outcomes quality initiative (KDOQI) quidelines state that estimation of GFR is the best overall indices of the Kidney function.

Causes of decreased level include Liver disease, SIADH.
CREATININE EGFR- EPI-- Kidney disease, outcomes quality initiative (KDOQI) guidelines state that estimation of GFR is the best overall indices of the Kidney function.
- It gives a rough measure of number of functioning nephrons. Reduction in GFR implies progression of underlying disease.
- The GFR is a calculation based on serum creatinine test.
- Creatinine is mainly derived from the metabolism of creatine in muscle, and its generation is proportional to the total muscle mass. As a result, mean creatinine generation is higher in men than in women, in younger than in older individuals, and in blacks than in whites.
- Creatinine is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate.
- When kidney function is compromised, excretion of creatinine decreases with a consequent increase in blood creatinine levels. With the creatinine test, a reasonable estimate of the actual GFR can be determined.
- This equation takes into account several factors that impact creatinine production, including and condens and race.

- estimate of the actual GFR can be determined.

  This equation takes into account several factors that impact creatinine production, including age, gender, and race.

  CKD EPI (Chronic kidney disease epidemiology collaboration) equation performed better than MDRD equation especially when GFR is high(>60 ml/min per 1.73m2).. This formula has less bias and greater accuracy which helps in early diagnosis and also reduces the rate of false positive diagnosis of CKD.

National Kidney Foundation (NKF) and the American Society of Nephrology (ASN).

Estimated GFR Calculated Using the CKD-EPI equation-https://testguide.labmed.uw.edu/guideline/egfr
Ghuman JK, et al. Impact of Removing Race Variable on CKD Classification Using the Creatinine-Based 2021 CKD-EPI Equation. Kidney Med 2022, 4:100471. 35756325
Harrison's Principle of Internal Medicine, 21st ed. pg 62 and 334

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc Intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist





Page 10 Of 16

View Report



PERFORMED AT :

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956





REF. DOCTOR:



PATIENT NAME: MRS.RANU PATEL

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001

ACCESSION NO: 0022XA002363 PATTENT ID : FH.12921812

CLIENT PATIENT ID: UID:12921812

ABHA NO

AGE/SEX :41 Years Female

DRAWN :13/01/2024 10:28:00 RECEIVED: 13/01/2024 10:28:35 REPORTED :13/01/2024 16:10:07

CLINICAL INFORMATION:

UID:12921812 REQNO-1650220

**Final** 

CORP-OPD

BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

**Test Report Status** 

Results

Biological Reference Interval . Units

Lower-than-normal levels may be due to: Agammagkobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist

PERFORMED AT:

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India

Tel: 022-39199222,022-49723322. CIN - U74899PB1995PLC045956

Email: -





Page 11 Of 16







REF. DOCTOR:



PATIENT NAME: MRS.RANU PATEL

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001

ACCESSION NO: 0022XA002363

PATIENT ID : FH.12921812 CLIENT PATIENT ID: UID:12921812

ABHA NO

Female AGE/SEX :41 Years :13/01/2024 10:28:00 DRAWN

RECEIVED: 13/01/2024 10:28:35 REPORTED :13/01/2024 16:10:07

CLINICAL INFORMATION:

UID:12921812 REQNO-1650220 CORP-OPD BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

**Test Report Status** 

Final

METHOD: ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

Results

Biological Reference Interval

Units

**BIOCHEMISTRY - LIPID** 

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL

102

35

< 200 Desirable

mg/dL

200 - 239 Borderline High

>/= 240 High

mg/dL

< 150 Normal 150 - 199 Borderline High

200 - 499 High >/=500 Very High

METHOD: ENZYMATIC ASSAY

NON HDL CHOLESTEROL

METHOD: CALCULATED PARAMETER

VERY LOW DENSITY LIPOPROTEIN METHOD: CALCULATED PARAMETER

HDL CHOLESTEROL

TRIGLYCERIDES

40

56

62

7.0

< 40 Low >/=60 High mg/dL

METHOD : DIRECT MEASURE - PEG LDL CHOLESTEROL, DIRECT

METHOD: DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT

< 100 Optimal

mg/dL

100 - 129 Near or above

optimal

130 - 159 Borderline High

160 - 189 High >/= 190 Very High

mg/dL

Desirable: Less than 130 Above Desirable: 130 - 159

Borderline High: 160 - 189

High: 190 - 219

Very high: > or = 220

</=30.0

mg/dL

2.6 Low

3.3 - 4.4 Low Risk

4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk

> 11.0 High Risk

METHOD: CALCULATED PARAMETER

CHOL/HDL RATIO

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 

Page 12 Of 16









Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







>6.0 High Risk

**REF. DOCTOR:** 



PATIENT NAME: MRS.RANU PATEL

CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001 ACCESSION NO: **0022XA002363**PATIENT ID : FH.12921812

CLIENT PATIENT ID: UID:12921812

ABHA NO

AGE/SEX :41 Years Female DRAWN :13/01/2024 10:28:00

RECEIVED : 13/01/2024 10:28:35 REPORTED :13/01/2024 16:10:07

#### CLINICAL INFORMATION:

UID:12921812 REQNO-1650220 CORP-OPD BILLNO-150124OPCR002520 BILLNO-150124OPCR002520

METHOD: CALCULATED PARAMETER

Diam's 19011.10, Oktober						
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units				
LDL/HDL RATIO	1.4	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate				

Interpretation(s)

politons.

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist

PERFORMED AT:

Agilus Diagnostics Ltd.
Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10,
Navi Mumbai, 400703
Maharashtra, India
Tal - 022-38108222 022-49723322

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Email: -

Page 13 Of 16





View Details

View Report









CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI.

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO: 0022XA002363

PATTENT ID : FH.12921812 CLIENT PATIENT ID: UID:12921812

ABHA NO

AGE/SEX :41 Years Female

DRAWN :13/01/2024 10:28:00 RECEIVED: 13/01/2024 10:28:35

REPORTED :13/01/2024 16:10:07

#### CLINICAL INFORMATION:

UID:12921812 REQNO-1650220

CORP-OPD

BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

**Test Report Status** 

Results

Biological Reference Interval Units

#### CLINICAL PATH - URINALYSIS

#### KIDNEY PANEL - 1

### PHYSICAL EXAMINATION, URINE

COLOR

PALE YELLOW

METHOD : PHYSICAL

APPEARANCE

CLEAR

METHOD: VISUAL

### CHEMICAL EXAMINATION, URINE

6.0

4.7 - 7.5

METHOD: REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD SPECIFIC GRAVITY

<=1.005

1.003 - 1.035

METHOD: REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)

**PROTEIN** 

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE

GLUCOSE

NOT DETECTED

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD

**KETONES** 

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN

BILIRUBIN

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT

**UROBILINOGEN** 

NORMAL

NORMAL

METHOD: REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRLICH REACTION)

NITRITE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE LEUKOCYTE ESTERASE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 

Dr. Rekha Nair, MD (Reg No. MMC 2001/06/2354) Microbiologist



Page 14 Of 16



Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956









CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR:

ACCESSION NO: 0022XA002363

PATIENT ID : FH.12921812 CLIENT PATIENT ID: UID:12921812

ABHA NO

AGE/SEX :41 Years Female

DRAWN :13/01/2024 10:28:00 RECEIVED :13/01/2024 10:28:35

REPORTED :13/01/2024 16:10:07

#### CLINICAL INFORMATION:

UID:12921812 REQNO-1650220

CORP-OPD

BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

Test Report Status Final	Results	Biological Reference 1	Interval Units					
MICROSCOPIC EXAMINATION, URINE								
RED BLOOD CELLS  METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	/HPF					
PUS CELL (WBC'S)  METHOD: MICROSCOPIC EXAMINATION	2-3	0-5	/HPF					
EPITHELIAL CELLS METHOD: MICROSCOPIC EXAMINATION	3-5	0-5	/HPF					
CASTS  METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED							
CRYSTALS METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED							
BACTERIA  METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED						
YEAST METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED						
REMARKS	NOTE :- URINARY MIC	ROSCOPIC EXAMINATION DON	IE ON URINARY					

CENTRIFUGED SEDIMENT

#### Interpretation(s)

(KISHATIS

Email: -

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist Ruche. N


Dr. Rekha Nair, MD (Reg No. MMC 2001/06/2354) Microbiologist



Page 15 Of 16

iew Details

View Report



Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI, MUMBAI 440001

ACCESSION NO: 0022XA002363

: FH.12921812

REF. DOCTOR :

CLIENT PATIENT ID: UID:12921812

ABHA NO

PATIENT ID

AGE/SEX :41 Years Female

DRAWN :13/01/2024 10:28:00 RECEIVED: 13/01/2024 10:28:35 REPORTED :13/01/2024 16:10:07

CLINICAL INFORMATION:

UID:12921812 REQNO-1650220 CORP-OPD BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

**Test Report Status** 

**Final** 

Results

Biological Reference Interval Units

### SPECIALISED CHEMISTRY - HORMONE

THYROID PANEL, SERUM

**T3** 

T4

146.7

Non-Pregnant Women

ng/dL

80.0 - 200.0 Pregnant Women

1st Trimester: 105.0 - 230.0 2nd Trimester: 129.0 - 262.0 3rd Trimester: 135.0 - 262.0

Non-Pregnant Women

µg/dL

5.10 - 14.10 Pregnant Women

1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70

Non Pregnant Women

µIU/mL

0.27 - 4.20

Pregnant Women (As per American Thyroid Association) 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000

METHOD: ELECTROCHEMILUMINESCENCE IMMUNOASSAY, COMPETITIVE PRINCIPLE

METHOD: ELECTROCHEMILUMINESCENCE IMMUNOASSAY, COMPETITIVE PRINCIPLE

TSH (ULTRASENSITIVE)

0.945

9.97

METHOD: ELECTROCHEMILUMINESCENCE, SANDWICH IMMUNOASSAY

Interpretation(s)

\*\*End Of Report\*\* Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) **Consultant Pathologist** 

PERFORMED AT:

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Email: -





Page 16 Of 16









CODE/NAME & ADDRESS : C000045507

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

**REF. DOCTOR:** 

ACCESSION NO: 0022XA002454

: FH.12921812 CLIENT PATIENT ID: UID:12921812

ABHA NO

PATIENT ID

AGE/SEX :41 Years Female

DRAWN :13/01/2024 15:04:00 RECEIVED: 13/01/2024 15:18:59

REPORTED :15/01/2024 11:07:42

#### CLINICAL INFORMATION:

UID:12921812 REQNO-1650220 CORP-OPD BILLNO-1501240PCR002520 BILLNO-1501240PCR002520

**Test Report Status** 

**Final** 

Units

#### CYTOLOGY

### PAPANICOLAOU SMEAR PAPANICOLAOU SMEAR

TEST METHOD SPECIMEN TYPE REPORTING SYSTEM SPECIMEN ADEQUACY METHOD: MICROSCOPIC EXAMINATION

MICROSCOPY

CONVENTIONAL GYNEC CYTOLOGY

TWO UNSTAINED CERVICAL SMEARS RECEIVED

2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY

SATISFACTORY

SMEARS STUDIED SHOW SUPERFICIAL SQUAMOUS CELLS, INTERMEDIATE SQUAMOUS CELLS, OCCASIONAL SQUAMOUS METAPLASTIC CELLS, OCCASIONAL CLUSTERS OF ENDOCERVICAL CELLS IN THE BACKGROUND OF FEW POLYMORPHS.

INTERPRETATION / RESULT

NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

#### Comments

PLEASE NOTE PAPANICOLAU SMEAR STUDY IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS, HENCE SHOULD BE INTERPRETED WITH CAUTION.

NO CYTOLOGICAL EVIDENCE OF HPV INFECTION IN THE SMEARS STUDIED.

\*\*End Of Report\*\* Please visit www.agilusdiagnostics.com for related Test Information for this accession



Dr. Akshay Dhotre, MD (Reg,no. MMC 2019/09/6377) Consultant Pathologist



Page 1 Of 1





PERFORMED AT :

Agilus Diagnostics Ltd. Hiranandani Hospital-Vashi, Mini Seashore Road, Sector 10, Navi Mumbai, 400703 Maharashtra, India Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -

Ç, 100B CL Title and professions Z F 50~ 0.50-100 HZ 1/13/2024 11:40:02 AM Δ2 Sinus rhythm......rises, inferior leads.......rflat/neg, II III aVF V4 Unconfirmed Diagnosis Chest: 10.0 mm/mV - BORDERLINE ECG -**M3** 72 Z Limb: 10 mm/mV RANU PATEL Speed: 25 mm/sec Female aVr€ aVL aVR 12 Lead; Standard Placement 44 22 -19 139 83 361 361 9 12921812 Device: 41 Years --AXIS--Rate PR QRSD QT QTC III QRS T H II

Hiranal@ars:20epWhcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN : 27AABCH5894D1ZG PAN NO : AABCH5894D



about:blank





## DEPARTMENT OF RADIOLOGY

Date: 15/Jan/2024

Name: Mrs. Ranu Patel

Age | Sex: 41 YEAR(S) | Female

Order Station: FO-OPD

Bed Name:

UHID | Episode No : 12921812 | 2621/24/1501 Order No | Order Date: 1501/PN/OP/2401/5415 | 13-Jan-2024

Admitted On | Reporting Date : 15-Jan-2024 15:25:53

Order Doctor Name: Dr.SELF.

### X-RAY-CHEST- PA

### Findings:

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Bony thorax are unremarkable.

DR. CHETAN KHADKE

M.D. (Radiologist)

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





Patient Name	- :	Ranu Patel	Patient ID	:	12921812
Sex / Age		F / 41Y 1M 24D	Accession No.	:	PHC.7306255
Modality	1:	US	Scan DateTime	:	13-01-2024 13:55:58
IPID No	•	2621/24/1501	ReportDatetime	1	13-01-2024 14:57:09

### **USG - WHOLE ABDOMEN**

LIVER is normal in size and echogenicity. No IHBR dilatation. No focal lesion is seen in liver. Portal vein appears normal in caliber.

**GALL BLADDER** is physiologically distended. Gall bladder reveals normal wall thickness. No evidence of calculi in gall bladder. No evidence of pericholecystic collection. **CBD** appears normal in caliber.

SPLEEN is mildly enlarged in size (13.6 cm) and normal in echogenicity.

**BOTH KIDNEYS** are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.

Right kidney measures 10.2 x 3.9 cm.

Left kidney measures 11.7 x 4.8 cm.

**PANCREAS**: Head and body of pancreas is visualised and appears normal. Rest of the pancreas is obscured.

URINARY BLADDER is normal in capacity and contour. Bladder wall is normal in thickness. No evidence of intravesical calculi.

TERUS is normal in size, measuring 8.1 x 5.9 x 3.4 cm. Endometrium measures 7 mm in thickness.

Both ovaries are normal. Right ovary measures 2.5 x 1.5 cm. Left ovary measures 3.3 x 2.3 cm.

No evidence of ascites.

## Impression:

Mild splenomegaly

DR. KUNAL NIGAM M.D. (Radiologist)

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





Patient Name	:	Ranu Patel	Patient ID	:	12921812
Sex / Age	:	F / 41Y 1M 24D	Accession No.	:	PHC.7306255
Modality		US	Scan DateTime	:	13-01-2024 13:55:58
IPID No	:	2621/24/1501	ReportDatetime	:	13-01-2024 14:57:09

### **USG-BREAST**

### **Findings:**

Bilateral breast parenchyma appears normal.

No evidence of solid or cystic lesion.

No dilated ducts are noted.

The fibroglandular architecture is well maintained.

Retromammory soft tissues appear normal.

No evidence of axillary lymphadenopathy.

### Impression:

· No significant abnormality detected.

Y.

DR. YOGINI SHAH
)MRD., DNB. (Radiologist)